Depo-Provera: The Mass Tort Opportunity Attorneys Should Not Miss in 2026

Depo-Provera as a Plaintiff Firm Acquisition Opportunity: Timing, Volume, and Economics

Depo-Provera client acquisition is currently generating cost-per-case metrics 40-60% below saturation benchmarks because the MDL (3140, N.D. Fla.) remains in early discovery with no bellwethers or settlements announced. This window—where case supply exceeds plaintiff bar penetration across most markets—typically closes within 18-24 months of active case filing. The underlying science (2023 Traore BMJ study: 5.6-fold increased risk) provides clear liability positioning. Early sourcing captures pre-saturation pricing while ad spend efficiency remains optimal.

The underlying science is bulletproof: the 2023 Traore study in the British Medical Journal found a 5.6-fold increased risk of intracranial meningioma in long-term Depo-Provera users. Pfizer, the manufacturer, has not settled or signaled any willingness to do so. The claimant pool remains largely unsaturated relative to other mass torts of similar vintage. And the causation evidence hasn't been tested in a U.S. courtroom yet—which means verdict outcomes are not yet constraining case valuations downward or inflating them beyond reality.

This post walks through the business case for Depo-Provera client acquisition as a plaintiff firm: litigation landscape, addressable claimant pool size, realistic advertising economics, intake qualification from your operations standpoint, and how MTAA manages this tort for firms across our network. By the end, you'll have a clear-eyed view of whether and when to deploy ad spend into this docket.

Litigation Landscape: MDL Status, Bellwether Timing, and What It Means for Case Value

MDL 3140 was formed in the Northern District of Florida in early 2024 under Judge M. Casey Rodgers. As of now, there are 3,000+ plaintiffs consolidated. The MDL is in early discovery phase. No bellwether trials have been scheduled; first bellwether selection and trials are estimated for 2026–2027.

For case acquisition strategy, this timing is critical. You are in the pre-verdict, pre-settlement phase—the narrow window when Depo-Provera client acquisition costs are lowest and case valuations are least distorted by trial outcomes or defense strength signals.

What does this mean operationally?

• No bellwether outcomes yet. Once the first bellwether trial happens—win, loss, or defense verdict—case valuation will narrow. If plaintiffs win decisively, case values rise and so do cost-per-lead numbers as more firms flood the market. If Pfizer wins or wins on causation, case values plummet and firms pull spend. Right now, you're acquiring cases at pre-signal pricing.
• Discovery is underway. This means defense is exchanging documents, experts are being designated, and the causation record is being built. Firms that acquire cases now will have 18–36 months of discovery production to strengthen cases before any trial. Case retention and satisfaction tend to be higher when clients see their case improving through active discovery work.
• No settlement offers from Pfizer yet. That's not a negative. It means Pfizer is not flagging settlement appetite, so firms acquiring cases now should not expect a quick global resolution. But it also means there's no downward pressure on case values from early settlement discussions. You're buying cases at full litigation value.
• Causation science is strong but untested in U.S. courts. The Traore study is robust (5.6x relative risk, published in a top-tier journal). But U.S. defense counsel will attack causation methodology, statistical significance, and applicability to the U.S. population. Cases acquired now are defensible on science, but defendants have not yet had a chance to sway a jury or judge on causation. This is a neutral-to-favorable signal for plaintiff acquisition.

Bottom line: You have 12–18 months of optimal Depo-Provera client acquisition pricing before bellwether selection and expert testimony lock in valuation ranges. After that, CPL and cost-per-signed-case will increase.

Claimant Pool Size and Saturation: Is There Still Volume to Capture?

Depo-Provera (medroxyprogesterone acetate) has been marketed in the United States since the 1990s. It's been one of the most widely prescribed injectable contraceptives, especially in Medicaid and Title X family planning programs. Epidemiologically, the addressable pool is large.

To qualify for litigation, a claimant must meet these criteria:

• Used Depo-Provera injections for 1+ years (5+ years is strongest)
• Diagnosed with intracranial meningioma (any grade, benign or atypical)
• Diagnosis confirmed by MRI, CT scan, or surgical pathology
• Meningioma required monitoring, medication, or surgical intervention
• Last injection within applicable statute of limitations or revival window

The meningioma diagnosis requirement is a hard gate. Not all Depo-Provera users have meningiomas. The addressable claimant pool is therefore constrained to the overlap of: (a) women who used Depo-Provera for extended periods, and (b) women diagnosed with intracranial meningioma. That's a much smaller absolute pool than, say, Roundup exposure (which touches millions) or opioid marketing (which spans decades and multiple classes of drugs).

Estimate: The realistic addressable claimant pool in the United States is 10,000–25,000 cases. The MDL currently has 3,000+. That leaves 7,000–22,000 remaining cases available for acquisition. Saturation is low to moderate—well below mass torts like talc or AFFF.

Geographically, Depo-Provera use was highest in areas with strong Medicaid and Title X family planning coverage, particularly in the South and Midwest. Urban and rural areas with high Title X penetration show higher incidence of users. But this is a nationwide tort with no geographic exclusion—a woman in Maine who used Depo-Provera for 6 years and developed a meningioma is just as eligible as a woman in Texas.

From a firm perspective: Depo-Provera client acquisition still has runway. You're not entering a market where every qualified claimant has been contacted by five other firms. If your firm has geographic reach or digital ad targeting capability, case capture is still achievable at reasonable economics.

Advertising Economics: CPL, CPS, and Channel Mix for Depo-Provera Client Acquisition

Here's where the rubber meets the road. You need to know what it will cost you to acquire and sign a case. Based on 15+ years managing $250M+ in Facebook ad spend for 600+ plaintiff law firms, I can give you real ranges.

Cost-Per-Lead (CPL) and Cost-Per-Signed-Case (CPS) Benchmarks

For Depo-Provera client acquisition in the current market:

• Facebook/Meta advertising: CPL ranges from $25–$55 per qualified lead (a lead that self-reports Depo-Provera use + meningioma diagnosis). CPS (fully signed case, after intake, qualification, and retainer execution) ranges from $1,800–$3,500 per case. The variance depends on creative quality, audience refinement, and your intake qualification funnel.
• Google Search (paid keywords): CPL is higher ($45–$85) because search intent is narrower and keyword competition is growing. CPS on search runs $2,200–$4,200. Search is best for high-intent users already researching meningioma and Depo-Provera litigation—but volume is lower than social.
• Display networks (banner ads on health/legal sites): CPL is lower ($15–$30) but lead quality is mixed. CPS can run $2,500–$4,500 because many leads convert more slowly or don't qualify. Best used for brand awareness or re-targeting existing leads.
• Native advertising (sponsored content on news/health sites): CPL is moderate ($35–$60), and CPS runs $1,500–$3,000. Native performs well for Depo-Provera because editorial context (health news, FDA updates) builds trust. High-intent audience.

The best-performing channel for Depo-Provera client acquisition remains Facebook/Meta because the audience is targeted (women, age 35–65, interests in health, contraception, women's health forums) and creative angles are proven. MTAA typically recommends a 60/20/20 split: 60% Meta, 20% Google Search, 20% native/display for this tort.

Creative Angles That Convert

Your ad creative must speak to the firm's intake operation, not the claimant's medical history. You're not diagnosing or explaining symptoms. You're reaching women who have already been diagnosed with meningioma and are wondering whether their Depo-Provera use was the cause.

High-converting creative angles for Depo-Provera client acquisition:

• "If you used Depo-Provera and were diagnosed with a brain tumor, a law firm may be able to help. Free confidential case review." (Straightforward, outcome-focused.)
• "Pfizer's Depo-Provera and meningioma: New study shows increased risk. If you used this contraceptive and developed a brain tumor, you may have a case." (Science-led, credibility anchor.)
• "Brain tumor after long-term Depo-Provera use? Get a free case evaluation from attorneys handling this lawsuit." (Direct, simple CTA.)
• "Intracranial meningioma and Depo-Provera: Were you injured? Law firm seeking cases for MDL 3140." (Transparent, docket-specific.)

Landing pages should be clear, fast-loading, and skepticism-proof. Include the Traore study citation, FDA updates, judge information (Judge Rodgers, N.D. Florida), and a simple form requiring only name, phone, basic medical history (years on Depo-Provera, meningioma diagnosis date, whether surgery was required). Keep friction low.

Intake & Qualification: How to Screen Cases and Build a Sticky Retainer Funnel

Not all leads that come in will sign. Your intake team needs a crisp qualification protocol to maximize conversion and case quality.

Intake Qualification Checklist

• Depo-Provera use timeline: Verify years of continuous use (1+ year minimum, 5+ years ideal). Get medical records confirming injection dates if available. Cases with 10+ years of continuous use are strongest.
• Meningioma diagnosis confirmation: Require imaging (MRI or CT scan) or pathology report. "My doctor said I had a brain tumor" is not enough. You need medical records documenting intracranial meningioma diagnosis.
• Intervention level: Did the meningioma require surgery, radiation, or ongoing monitoring? Cases requiring surgery are higher-value. Asymptomatic meningiomas found incidentally and not treated are lower-value.
• Timeline alignment: Was the meningioma diagnosed during or shortly after extended Depo-Provera use? Strongest cases show diagnosis within 5 years of last injection. Diagnosis 15+ years after last injection weakens causation narrative.
• Statute of limitations and revival windows: Verify the claimant's statute of limitations has not run. Most states allow suit within 2–5 years of diagnosis or discovery. Some have revival windows (e.g., Florida allows revival of claims filed within 4 years of MDL formation). Screen for timeliness before signing.
• Prior litigation history: Has the claimant already retained counsel or filed a claim elsewhere? If yes, verify whether the claim is still open or whether prior counsel was discharged. Avoid cases where claimants are forum-shopping or have burning past relationships with other firms.

Your intake form should capture these data points before a phone call. This pre-qualification step saves time and improves case quality. Leads that fail the meningioma diagnosis requirement or statute of limitations should be disqualified quickly.

Retainer Flow and Case Retention

Once a prospect passes intake qualification, move to retainer quickly. At MTAA, we see case retention and client satisfaction improve when:

• Firm sends a welcome packet within 24 hours: Include the retainer agreement, HIPAA authorization, medical records release forms, and a one-page summary of the MDL status, litigation timeline, and fee structure. Clear communication builds trust.
• Intake counsel or a paralegal calls within 48 hours: Confirm medical details, discuss litigation expectations (timeline, settlement odds, trial possibility), and answer questions. Personal contact reduces client dropout.
• Firm obtains medical records proactively: Don't ask the client to pull records from three different hospitals. Have your firm request them. Clients who see active case work stay engaged.
• Send periodic case status updates: Even in early discovery phases, send quarterly updates summarizing MDL activity, discovery deadlines, and next steps. Radio silence causes client doubts and referral withdrawal.

For Depo-Provera cases specifically, retention tends to be high because the injury is objective (meningioma is observable and documented), the science is clear, and clients are typically highly motivated (brain tumor diagnosis). Your retention challenge is lower than in torts with soft-tissue injuries or diffuse exposure. Focus on responsiveness and transparency.

How MTAA Manages Depo-Provera Client Acquisition

MTAA has been running Depo-Provera client acquisition campaigns for plaintiff firms since mid-2024, as soon as the MDL formed. Here's what we bring to this tort:

• Transparent cost-plus pricing: We charge only the actual ad spend (Facebook, Google, native, etc.) plus a 15% management fee. No hidden production fees or markup on media. For a $50,000/month campaign, you pay $50,000 in ad spend + $7,500 in MTAA fees. You see the media invoice and know exactly what you're paying for reach.
• Proven creative and audience targeting: We've tested hundreds of ad variations across 600+ firms and 100+ torts. For Depo-Provera, we know which creative angles drive qualified leads (not just clicks), which audience cohorts have the highest case-sign rate, and which landing pages convert best. We don't start from scratch; we apply tested frameworks.
• Real-time optimization: Our team monitors CPL, click-through rates, landing page conversion, and cost-per-signed-case daily. If a creative is underperforming, we pause it and pivot to higher performers. Monthly reporting shows you exactly where your money went, what was generated, and what future spend should target.
• Full campaign management: We handle creative development (copy, design, video), media buying across platforms, landing page optimization, and tracking/attribution. Your firm focuses on intake and case work; we handle the digital marketing heavy lifting.
• Scaling capability: Whether you want to run $10,000/month

  Ready to Build Your Caseload?

  Get a free campaign analysis from Mass Tort Ad Agency.

  $250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.

  Schedule a Free Consultation →

  Frequently Asked Questions: Advertising Depo-Provera Cases

  What is the current cost per lead and cost per signed case for Depo-Provera client acquisition?

  Because the MDL is in early discovery with no bellwethels or settlements yet, case acquisition costs remain significantly lower than mature mass torts—typically $150–$300 per qualified lead depending on geography and channel, with signed case costs in the $2,500–$4,500 range. These economics improve further in underserved markets where plaintiff bar saturation hasn't yet driven up advertising competition and lead costs.

  How large is the addressable claimant pool for Depo-Provera meningioma cases, and is the market oversaturated?

  The addressable claimant pool includes approximately 7.5+ million long-term Depo-Provera users in the U.S., with epidemiological data suggesting tens of thousands of meningioma cases attributable to the drug. Relative to other mass torts of similar vintage, the plaintiff bar has not yet saturated most regional markets, meaning significant volume remains available for disciplined acquisition strategies.

  What advertising channels and creative approach does MTAA recommend for Depo-Provera case sourcing?

  MTAA recommends a multi-channel approach combining digital display and search (targeting women 35–65 with meningioma-related keywords), social media (Facebook, Instagram with educational creative), and regional broadcast in underserved markets. MTAA's cost-plus model ties your firm's ad spend to qualified leads and signed cases, ensuring you pay only for results while retaining control over intake qualification standards.

  Why is the Depo-Provera MDL in early discovery a strategic advantage for case acquisition?

  Early-stage MDL positioning (no bellwethels, no verdicts, no settlements) means case valuations are not yet constrained by courtroom outcomes, advertising competition remains moderate, and claimant awareness is still building. This window allows firms to acquire cases at the lowest cost-per-signed-case before the litigation matures and supply tightens or demand inflates valuations beyond realistic risk-adjusted returns.

  What causation and scientific evidence supports Depo-Provera meningioma litigation from a firm risk standpoint?

  The 2023 Traore study in the British Medical Journal established a 5.6-fold increased risk of intracranial meningioma in long-term Depo-Provera users, providing robust epidemiological causation evidence. With Pfizer showing no settlement signals and no U.S. courtroom verdicts yet, the causation science remains untested but scientifically credible, positioning the case inventory as viable without artificial verdict-driven valuation inflation.